Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081822 · ClinicalTrials.gov registry record · Phase 1
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00081822 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants.
The verdict
NCT00081822, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended phase II dose of clofarabine when administered in combination with standard dose Ara-C to older (\>=60 years of age) patients with newly diagnosed acute myeloid leukemia (AML).
Interventions
- DRUG clofarabine
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081822
The ClinicalTrials.gov registry entry for NCT00081822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clofarabine is the first listed.
NCT00081822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081822 about?
NCT00081822 is a clinical study titled "Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia". The purpose of this study is to determine the recommended phase II dose of clofarabine when administered in combination with standard dose Ara-C to older (\>=60 years of age) patients with newly diagnosed acute myeloid leukemia (AML).
What is the current status of trial NCT00081822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2004-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00081822?
The interventions under investigation include: clofarabine (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00081822?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.